RBRatul Bhowmik

Ratul Bhowmik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ratul Bhowmik has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Machine Learning Models and Structure‐Based Antibacterial Drug Discovery of the Key ABC Transporter Maltose‐Binding Protein A

    by Anupama Binoy, Ratul Bhowmik, Preena S. Parvathy, C. Gopi Mohan

    Generating new and efficient drugs through machine learning‐assisted quantitative structure–activity relationships (ML‐QSAR) has become a promising strategy for addressing multidrug‐resistant gram‐negative bacterial infections. We developed robust ML‐QSAR models using Genetic Function Approximation (GFA), Support Vector Machine (SVM), and Artificial Neural Network (ANN) methods to predict the activity of experimentally known quinoline‐based MsbA inhibitors, aiming to create more effective antibacterial drugs. The ML models were built using eight significant molecular descriptors: B09[N‐Cl], CATS3D_04_AA, F06[N‐O], G2i, molecular weight (MW), Mor04p, VE1sign_B(s), and VE1sign_Dz(i), along with 279 molecular fingerprints to predict the MsbA inhibition activity of quinoline‐based compounds. The molecular descriptor‐based SVM model achieved an R² of 0.9891 and a q² cross‐validation correlation of 0.9388. In contrast, the molecular fingerprint‐based SVM model had an R² of 0.9981 and a q² cross‐validation correlation of 0.7584, making it the best‐performing model. The robustness of these developed models was further validated through various internal, external, and applicability domain analyses. The most active compounds identified in this data set, compounds 31 and 40, were subsequently used to generate 62 new quinoline‐based compounds. Additionally, three modelled quinoline‐based inhibitors, M28, N7, and N23, demonstrated excellent bioactivity, binding affinity, and pharmacokinetic profiles. To support further research, the fingerprint‐based ML‐QSAR model is available as a web application, MsbA‐Pred ( https://msba-mohan-amrita.streamlit.app/ ), which allows users to predict MsbA inhibitory activity from any device.

  • Open Access

    Integrated Graph-Based Models Unveil Carbonic Anhydrase VIII, X, XI Expression in Cancer and Neurological Diseases

    by Ashok Aspatwar, Rajarshi Ray, Ratul Bhowmik, Seppo Parkkila

    Carbonic anhydrases are metalloenzymes found both in vertebrates and invertebrates. The CAs catalyze the reversible hydration of CO2 to bicarbonate and H+ ions and play a significant role in respiration, transport of CO2, pH homeostasis, electrolyte secretion, and biosynthetic reactions. The enzymatic activity of CAs is due to the coordination of Zn2+ in the active site by three histidine residues; however, in humans, there are three CAs known as CA-related proteins (CARPs) that are catalytically inactive due to the absence of one or more of the three histidine residues required for the coordination of the Zn2+ in the active site. Studies have shown that CARPs are expressed in all parts of the brain and are overexpressed in some cancers suggesting that the CARPs play a crucial role in neurological disorders and the development of cancer. However, the precise physiological roles of CARPs are still an enigma. Therefore, in the present study, we present an end-to-end biological workflow utilizing various methodologies involving statistical procedures to compute similarity across the CARPs by assessing the occurrence of biological parameters shared across them and determining potential biomarkers in the form of transcription factors, coexpressed genes, and phenotypes, respectively, which could have possible expression levels to activate the CARPs activity along the disease pathways. Additionally, we proposed a One Health model by analyzing various drugs and chemical candidates that would have potential therapeutic effects in suppressing the biomarkers associated with disease development, hence providing a therapeutic response against the negative modulation of CARPs within humans.

  • Open Access

    RETRACTED: Exploring the applications of formulation-based drug development strategies in neurological disorders using artificial intelligence and machine learning approaches

    by Ashok Aspatwar, Ranajit Nath, Ratul Bhowmik, Rajesh Jesudasan

    This content was retracted at the authors' request to allow for corrections to the preprint. The study of artificial intelligence (AI), a multidimensional field, empowers machines with the ability to understand, reason, learn, and perform tasks autonomously. As a pivotal branch of computer science, AI excels in analyzing complex medical data and uncovering significant relationships for diverse diagnostic purposes. In neurology, innovative AI techniques have revolutionized diagnostics, management, and outcome prediction, opening new avenues for tackling neurological disorders. AI encompasses two key subsets: machine learning (ML) and deep learning (DL), which have gained immense popularity for predicting bioactivity, toxicology, physical and chemical properties, formulation quality, and drug-target interactions. The complexity of neurological diseases (ND) presents unique challenges in developing treatments for the central nervous system (CNS), given obstacles like the blood-brain barrier and high medication attrition rates. However, AI algorithms, leveraging vast datasets, efficiently analyze, interpret, and predict unknown facts, significantly accelerating CNS drug discovery. Deep learning architectures have furthered our understanding of AI's potential to address complex CNS disease issues, transforming the drug development landscape. This review delves into AI, ML, and their applications in advancing CNS drug and formulation development. It provides comprehensive, up-to-date insights on AI/ML advancements in neurology, emphasizing nanoparticle-based drug delivery systems. Additionally, the review covers ML algorithms' roles in de novo drug design, structure-based drug design, ligand-based drug design, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, and drug repurposing. Despite notable progress, significant challenges remain in enhancing AI's practical application in neurology. Overcoming these hurdles requires compiling extensive data and developing interpretable AI systems, paving the way for groundbreaking advancements in CNS drug development.


  • Open Access

    RETRACTED: Herbal-based nanosystems: A novel drug-delivery treatment procedure against neurodegenerative disorders

    by Ashok Aspatwar, Ranajit Nath, Ratul Bhowmik, Rajesh Jesudasan

    This content was retracted at the authors' request to allow for corrections to the preprint. Nanotechnology has had a profound influence on human existence. Overcoming the many difficulties presented by various disorders, particularly neurological disorders (NDs), is a crucial approach. Various types of nanomaterials, including lipid nanoparticles, nanoliposomes, nano-micelles, polymer nanoparticles, and metal nanoparticles, along with different methods of transportation arrangements such as poly lactic o-glycolic acid, lactoferrin, and poly butyl cyanoacrylate, have the potential to greatly enhance the effectiveness, reduce the risk of negative outcomes, improve stability, and enhance the pharmacokinetics of many medications. Neurological disorders (NDs) are a subset of debilitating diseases that have a significant impact on a large population worldwide. Prior studies have shown that various formulations including nanotechnology, derived from a range of natural substances such as curcumin, quercetin, Ginkgo Biloba, and nigella sativa, significantly improve the well-being of persons with neurological disorders. The blood-brain barrier (BBB) is the primary obstacle preventing the passage of medications into the central nervous system (CNS), posing a challenge in the treatment of neurological disorders (NDs). . Engineered nanoparticles with altered physicochemical characteristics, ranging in size from 1 to 100 nm, can be utilized to enhance the effectiveness, cellular uptake, selective delivery, and distribution of specific particles to the brain. Nanoparticles derived from therapeutic plants and their constituents, known as phytomedicine from nano, have gained recognition for their abundant supply, ability to precisely target the brain, and reduced risk of adverse effects. These nanoparticles are increasingly important in the development of advanced neuro-therapeutics. This paper discusses the potential and ongoing advancements in using the combination of phytomedicine and nanotechnology for the treatment of neurological disorders. To summarize, herbal-based nanosystems, either alone or in combination with other drugs, demonstrate potential efficacy in the treatment of neurological disorders..


  • Open Access

    A multidimensional network-based approach to elucidate the molecular mechanism underlying tuberculosis and HIV coinfection

    by Ashok Aspatwar, Ratul Bhowmik, Sagar Singh Shyamal, Rajarshi Ray, Fabrizio Carta, Claudiu T. Supuran, Seppo Parkkila

    Tuberculosis (TB) and human immunodeficiency virus (HIV) coinfection is a severe global health challenge with high morbidity and mortality rates. In this study, we employed a novel bioinformatics approach to gain a comprehensive understanding of the state of TB/HIV coinfection. Using a multidimensional graph-based clustering methodology, we identified several key pathways associated with infectious and autoimmune diseases, immune and inflammatory responses, cardiovascular dysfunctions, and metabolic processes. We identified therapeutic biomarkers regulated by established therapeutic chemicals and developed robust machine learning-based quantitative structure-activity relationship (ML-QSAR) models to identify effective drug candidates. Our models successfully identified S5105 proanthocyanidin as a promising modulator of the key inflammatory biomarkers TNF, IL1B, and IFNG. Furthermore, we analyzed the influence of environmental factors, such as arsenic, air pollutants, and carbon monoxide, on the progression and occurrence of TB/HIV coinfection. Our findings revealed that these toxicants can trigger a cascade of inflammatory responses, leading to lung fibrosis and a cytokine storm that exacerbates immune dysregulation in coinfected individuals. Additionally, the impact of air pollutants on cardiovascular health and neurological complications, such as AIDS-Dementia Complex, adds to the complexity of managing TB/HIV coinfection. Again, with the findings of multidimensional graphs, we tried to elucidate the correlation between the air quality indices and the occurrence of TB/HIV coinfection. The models highlighted particulate matter (PM)10 and PM2.5 concentrations as critical predictors, indicating that poor air quality is positively correlated with higher rates of HIV testing among TB patients and an increased percentage of HIV-positive TB patients on antiretroviral therapy (ART). This suggests regions with worse air quality may have more comprehensive health monitoring. By identifying these associations, we can better understand how arsenic and air pollutants might contribute to immune deterioration and disease progression in TB and HIV patients. Thus, a multidimensional methodology can significantly enhance drug discovery and environmental toxicological efforts by integrating diverse data sources and analytical techniques to uncover complex interactions, identify potential therapeutic targets, and assess the impact of environmental toxins on health with greater precision.


  • Open Access

    RETRACTED: Pharmacokinetics-Pharmacodynamics (PK-PD) Modeling: A translational path to brain-targeted drug delivery

    by Ashok Aspatwar, Ratul Bhowmik, Ranajit Nath, Bhabani Sankar Satapathy, Puja Saha, Rajesh Ghosh, Seppo Parkkila

    This content was retracted at the authors' request to allow for corrections to the preprint. Pharmacokinetic-pharmacodynamics (PK/PD) modeling has been recognized as an essential tool for the planning and execution of clinical pharmacology investigations throughout the formulation development process. The utilization of PK/PD modeling to optimize dosage recommendations and therapeutic medication monitoring is on the rise, and PK/PD model-based dose individualization is going to play a crucial role in personalized medicine. In recent years, higher costs and low productivity in drug development have got a lot of attention. Fewer than 10% of innovative medications that survive clinical trials are commercialized, while many more fail in preclinical research. Based on preclinical and clinical data, the FDA now defines model-based drug development as a key tool in the assessment of therapeutic efficacy and safety of medications. As successful drug delivery to central nervous system (CNS) diseases has been a tough challenge, effective use of PK/PD models can permit merging data from clinical trials with quantified exposure and provide highly convincing explanations for disparities in the results of distinct investigations. To improve CNS therapies and drug development, details of inter-species and inter-condition variations are needed to enable target site pharmacokinetics and associated CNS effects between disease states. The present review covers the potential of PK/PD modeling in the current scenario of drug development with a special emphasis on CNS-based targeted delivery. Additionally, challenges associated with the field have also been addressed.


  • Open Access

    A data and knowledge-driven integrated modeling approach to organ-specific Tuberculosis subtype discovery: A one health paradigm

    by Ashok Aspatwar, Rajarshi Ray, Ratul Bhowmik, Sagar Singh Shyamal, Ajay Manaithiya, Fabrizio Carta, Claudiu Supuran, Seppo Parkkila

    Tuberculosis (TB) is caused by the bacterium Mycobacterium tuberculosis (Mtb) and is globally known for its high mortality rate due to its active pathogenic properties, which often result in inflammatory responses along the tissues they localize, causing necrosis of surrounding cells and even organ failure. Based on the organ and tissue-specific infection caused by Mtb, TB is classified into two categories: pulmonary TB (PTB) and extrapulmonary TB (EPTB), of which the latter is known for its infecting capability across various organs like the brain, liver, lymph nodes, etc. Hence, to analyze the biological pathways and genes enriched within the progression of PTB into EPTB, along with the detailed analysis of biological enrichment and relationships shared among the various categories of EPTB, we present a One Health model that utilizes series of computational clustering methodologies to analyze the similar genes and biological pathways that correspond to the disease types of EPTB, along with the development of knowledge graphs to visualize the biological interactions among various chemicals and genes that contribute to therapeutic mechanisms of action to treat the disease symptoms and correspond to both PTB and EPTB, respectively. Ultimately, we present a Read Across QSAR (RASAR) model that uses machine learning approaches to predict the therapeutic nature of novel chemical candidates by assessing their morphological descriptors. Henceforth, by deploying a series of end-to-end computational strategies, we successfully analyze the complex biological data associated with the pathogenesis of EPTB and establish their significance with PTB, along with screening out potential biological pathways, genes, and chemicals that specifically correspond to the development of TB within patients.

  • Open Access

    APV9WR: An Integrated Web Resource of Alpha papillomavirus 9 for Genomics, Proteomics, Phylogenetic and Therapeutic Analysis

    by Akanksha Kulshreshtha, Vasu Goel, Akriti Verma, Sparsh Goel, Susha Dinesh, Sameer Sharma, Ratul Bhowmik, Ashok Aspatwar

    Purpose: Alphapapillomavirus 9 is a virus belonging to the Papillomaviridae family. It has a close genetic relationship with high-risk HPV-16 and other HPV strains such as HPV-31, HPV-52, HPV-35, HPV-58, HPV-67, and HPV-35. This virus is responsible for causing warts and malignant tumors and is responsible for about 75% of cervical malignancies and pre-cancerous lesions worldwide. As a result, it requires specialized research and attention. Our goal is to create a comprehensive resource that can assist researchers and scientific groups in their work. Material and Methodology: A total of 1230 full genome sequences and 9140 protein sequences were obtained from GenBank and NCBI Virus, respectively. Further Phylogenetic Analysis, Codon usage and context analysis, CpG islands analysis, Glycosylation sites, Diagnostic Primers, B cell Epitopes and MHC I and MHC II binders were identified and analyzed using relevant Bioinformatics tools and Python program Results: APV9WR is a web resource that was developed after analysis. Our data indicate that HPV 35 and HPV 38 have the most genomic diversity. From codon usage analysis, it was observed that AAA, AUU, UAU, UGU, and UUU are the most used codons, while ACG, CCG, CGA, CGG, CGU, GCG, and UCG are some of the unusual codons in APV9 nucleotide sequence with accession id - LC626346.1 . We found 4714 CpG island locations in 1230 complete nucleotide sequences of APV9, and only 663 CpG island locations were unique. Further N-linked glycosylation, O-linked glycosylation, diagnostic primers, Potential B-cell epitopes and MHC I and MHC II binders were also analyzed and tabulated. Conclusion: We have consolidated basic information about the virus, such as entire genomic sequences and proteins. It primarily comprises a wide range of studies and outcomes, including genome alignment, phylogenetic inferences, codon context and usage bias, and important CpG island statistics. Furthermore, primers for molecular diagnostics were identified, and glycosylation sites were located and investigated. Most significantly, potential therapeutic elements such as vaccine epitopes and obtaining potential information about them were investigated. Our collective effort on this tool is meant to serve the greater good of the research community for therapeutic intervention for Alphapapillomavirus 9. Using this link https://apv9nsut.web.app will take you to the web app.

  • Open Access

    A multi-dimensional systems biology approach to elucidate the mechanism of action of Mycobacterium tuberculosis γ-carbonic anhydrase inhibitors

    by Ashok Aspatwar, Ajay Manaithiya, Ratul Bhowmik, Kunal Bhattacharya, Rajarshi Ray, Sagar Singh Shyamal, Fabrizio Carta, Claudiu Supuran, Seppo Parkkila

    Background: Mycobacterium tuberculosis (Mtb) carbonic anhydrases (CAs) are critical enzymes that regulate pH by converting CO2 to HCO3-, essential for Mtb's survival in acidic environments. Inhibiting γ-CAs presents a potential target for novel antituberculosis drugs with unique mechanisms of action. Objective: This study aimed to explore the biological connections underlying Mtb pathogenesis and investigate the mechanistic actions of antituberculosis compounds targeting the Cas9 protein. Methods: We employed homology modeling and virtual screening to identify compounds with high binding affinities for Cas9 protein. This study used the homology modeling approach employing high-quality AlphaFold DB models for γ-CA. Furthermore, the systems biology approach was used for analyzing the mechanistic modeling of compounds, integrating data on genes, pathways, phenotypes, and molecular descriptors. Single-cell RNA sequencing was also conducted to profile gene expression. Results: Three compounds, F10921405, F08060425, and F14437079, potentially binding to Cas9 protein, have been identified. F10921405 and F08060425 showed significant overlap in their effects on pathways related to the immune response, while F14437079 displayed distinct mechanistic pathways. Expression profiling revealed high levels of genes such as PDE4D, ROCK2, ITK, MAPK10, and SYK in response to F1092-1405 and F0806-0425, and MMP2 and CALCRL in response to F1443-7079. These genes, which play a role in immune modulation and lung tissue integrity, are essential to fight against Mtb. Conclusion: The molecular relationship and pathways linked to the mentioned compounds give the study a holistic perspective of targeting Mtb, which is essential in designing specific therapeutic approaches. Subsequent research will involve experimental validation to demonstrate the efficacy of the promising candidates in Mtb infections.

  • Open Access

    WITHDRAWN: Physiological modeling into the metaverse of Mycobacterium Tuberculosis Beta CA inhibition mechanism

    by Simone Giovannuzzi, Sagar Singh Shyamal, Ratul Bhowmik, Rajarshi Ray, Ajay Manaithiya, Fabrizio Carta, Seppo Parrkila, Ashok Aspatwar, Claudiu T. Supuran

    Withdrawal Statement: The authors have withdrawn their manuscript owing to the inability to complete the revisions or follow up on the manuscript at this time, due to personal circumstances. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.